Biotech Values

[mikeg]

NNVC - anybody been keeping an eye on this one?

The Company also developed initial drug candidates against Dengue Viruses. These early drug candidates have already exhibited a substantial in vivo effectiveness of 50% survival of animals in an ADE-challenge model. ADE stands for antibody-dependent enhancement of dengue infection. This is a very serious effect which leads to severe dengue and fatalities in large numbers of patients that contract dengue virus of a different type after having had a dengue infection previously. There are currently no treatments or vaccines available for dengue or dengue hemorrhagic fever. We plan to improve these early anti-dengue and anti-HSV candidates further in the ensuing year and then advance into pre-IND application stage.